Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?

The presence of hypoxia is a general feature of most solid malignancies, and hypoxia is considered as one of major factors for anticancer therapy failure. Carbonic anhydrase IX (CAIX) has been reported to be an endogenous hypoxia marker, CAIX monoclonal antibodies, their segments and inhibitors are developed for CAIX imaging. However, growing evidence indicates that CAIX expression under hypoxia condition may be cancer cell lines or cancer-type dependent. Here we review the current literature on CAIX and discuss the advantage and limitation of CAIX as a target for tumor hypoxia imaging. Accordingly, CAIX would be unreliable as a universal target for cancer and tumor hypoxia visualization.

[1]  Xindao Yin,et al.  The Reverse Warburg Effect and 18F-FDG Uptake in Non–Small Cell Lung Cancer A549 in Mice: A Pilot Study , 2015, The Journal of Nuclear Medicine.

[2]  A. Civelek,et al.  18F-Fluorodeoxyglucose Uptake and Tumor Hypoxia: Revisit 18F-Fluorodeoxyglucose in Oncology Application , 2014, Translational oncology.

[3]  Masakazu Toi,et al.  Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials , 2014, Japanese journal of clinical oncology.

[4]  P. V. van Diest,et al.  The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression , 2013, BMC Cancer.

[5]  P. Lambin,et al.  Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. , 2013, Journal of medicinal chemistry.

[6]  G. Semenza,et al.  Role of hypoxia-inducible factors in breast cancer metastasis. , 2013, Future oncology.

[7]  G. Santoni,et al.  Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma , 2013, BioMed research international.

[8]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[9]  R. S. Johnson,et al.  Tumour oxygenation: implications for breast cancer prognosis , 2013, Journal of internal medicine.

[10]  A. Grosu,et al.  Hypoxia in Head and Neck Tumors: Characteristics and Development during Therapy , 2013, Front. Oncol..

[11]  H. Gali-Muhtasib,et al.  Targeting hypoxia for sensitization of tumors to radio- and chemotherapy. , 2013, Current cancer drug targets.

[12]  W. Oyen,et al.  Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. , 2013, Immunotherapy.

[13]  Yongzhi Yang,et al.  HIFs, angiogenesis, and cancer , 2013, Journal of cellular biochemistry.

[14]  L. Szablewski.  Expression of glucose transporters in cancers. , 2013, Biochimica et biophysica acta.

[15]  K. Williams,et al.  Carbonic anhydrase IX as a target for metastatic disease. , 2013, Bioorganic & medicinal chemistry.

[16]  W. Sly,et al.  Structure, function and applications of carbonic anhydrase isozymes. , 2013, Bioorganic & medicinal chemistry.

[17]  Ceen-Ming Tang,et al.  Hypoxia‐inducible factor‐1 as a therapeutic target in cancer , 2013, Journal of gastroenterology and hepatology.

[18]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[19]  C. Supuran,et al.  In Vivo Imaging and Quantification of Carbonic Anhydrase IX Expression as an Endogenous Biomarker of Tumor Hypoxia , 2012, PloS one.

[20]  M. Proescholdt,et al.  Function of carbonic anhydrase IX in glioblastoma multiforme. , 2012, Neuro-oncology.

[21]  Huijie Jiang,et al.  Tumor Microenvironment–Dependent 18F-FDG, 18F-Fluorothymidine, and 18F-Misonidazole Uptake: A Pilot Study in Mouse Models of Human Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.

[22]  C. Supuran,et al.  Carbonic anhydrase IX as a target for designing novel anticancer drugs. , 2012, Current Medicinal Chemistry.

[23]  Claudiu T. Supuran,et al.  Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics , 2012, Oncotarget.

[24]  Y. Qi,et al.  Preliminary biological evaluation of 125I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors , 2011, Nuclear medicine communications.

[25]  J. Humm,et al.  Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250 , 2011, The Journal of Nuclear Medicine.

[26]  J. Pouysségur,et al.  pH control mechanisms of tumor survival and growth , 2011, Journal of cellular physiology.

[27]  P. Argani,et al.  Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. , 2010, American journal of clinical pathology.

[28]  C. Supuran,et al.  Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. , 2010, Current pharmaceutical design.

[29]  P. Lambin,et al.  Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. , 2010, Nuclear medicine and biology.

[30]  W. Oyen,et al.  Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. , 2010, European urology.

[31]  Valerie A Longo,et al.  Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts , 2010, PloS one.

[32]  J. Pouysségur,et al.  High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer , 2010, British Journal of Cancer.

[33]  C. Ling,et al.  High 18F-FDG Uptake in Microscopic Peritoneal Tumors Requires Physiologic Hypoxia , 2010, Journal of Nuclear Medicine.

[34]  C. Supuran,et al.  Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. , 2010, Biochimica et biophysica acta.

[35]  G. Song,et al.  Role of hypoxia in the hallmarks of human cancer , 2009, Journal of cellular biochemistry.

[36]  Masahiro Hiraoka,et al.  The HIF-1-active microenvironment: an environmental target for cancer therapy. , 2009, Advanced drug delivery reviews.

[37]  E. Stanbridge,et al.  Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[38]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[39]  J. Bussink,et al.  Molecular aspects of tumour hypoxia , 2008, Molecular oncology.

[40]  C. Ling,et al.  Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. , 2007, Cancer research.

[41]  J. Pouysségur,et al.  Oxygen, a source of life and stress , 2007, FEBS letters.

[42]  A. Harris,et al.  Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression , 2007, Journal of Molecular Medicine.

[43]  C. Supuran,et al.  Targeting tumor-associated carbonic anhydrase IX in cancer therapy. , 2006, Trends in pharmacological sciences.

[44]  W. Oyen,et al.  Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. , 2006, Cancer biotherapy & radiopharmaceuticals.

[45]  C. Perneel,et al.  Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. , 2006, International journal of radiation oncology, biology, physics.

[46]  P. Vaupel,et al.  Carbonic Anhydrase IX Expression and Tumor Oxygenation Status Do Not Correlate at the Microregional Level in Locally Advanced Cancers of the Uterine Cervix , 2005, Clinical Cancer Research.

[47]  J. Bussink,et al.  Hypoxic cell turnover in different solid tumor lines. , 2005, International journal of radiation oncology, biology, physics.

[48]  P. Malfertheiner,et al.  Expression of carbonic anhydrase 9 at the invasion front of gastric cancers , 2005, Gut.

[49]  C Clifton Ling,et al.  Dependence of FDG uptake on tumor microenvironment. , 2005, International journal of radiation oncology, biology, physics.

[50]  J. Pastorek,et al.  Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin , 2003 .

[51]  W. Sly,et al.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.

[52]  E. Rofstad.  Microenvironment-induced cancer metastasis , 2000, International journal of radiation biology.

[53]  G. Hanks,et al.  Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[55]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[56]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[57]  M. Dewhirst,et al.  The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. , 1995, British Journal of Cancer.

[58]  R. Kettmann,et al.  Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. , 1994, Oncogene.

[59]  S. Pastoreková,et al.  A novel quasi-viral agent, MaTu, is a two-component system. , 1992, Virology.

[60]  P. Vaupel,et al.  Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. , 1991, Cancer research.

[61]  L. Révész,et al.  Survival of cells in anoxia. , 1968, British Journal of Radiology.

[62]  G. Gifford.  SOME EFFECTS OF ANAEROBIOSIS ON THE GROWTH AND METABOLISM OF HELA CELLS. , 1963, Experimental cell research.

[63]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[64]  S. Dedhar,et al.  Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. , 2014, Sub-cellular biochemistry.

[65]  R. Gillies,et al.  Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. , 2014, Sub-cellular biochemistry.

[66]  R. Bristow,et al.  Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. , 2014, Advances in experimental medicine and biology.

[67]  J. Pastorek,et al.  Carbonic anhydrase IX: regulation and role in cancer. , 2014, Sub-cellular biochemistry.

[68]  P. Glazer,et al.  FoCUS: 50 YEARS oF DNA REPAiR: THE YALE SYMPoSiUM REPoRTS , 2013 .

[69]  A. Civelek,et al.  (18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings. , 2013, American journal of nuclear medicine and molecular imaging.

[70]  A. Scott,et al.  A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. , 2007, Cancer immunity.

[71]  C. Koch,et al.  Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. , 2003, Advances in experimental medicine and biology.

[72]  P Lambin,et al.  Hypoxia as a target for combined modality treatments. , 2002, European journal of cancer.

[73]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[74]  P Vaupel,et al.  Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. , 1994, Advances in experimental medicine and biology.

[75]  C. Koch,et al.  Plateau phase in growth induced by hypoxia. , 1973, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[76]  C. Koch,et al.  The effect of hypoxia on the generation time of mammalian cells. , 1973, Radiation research.